Page last updated: 2024-12-07
flazasulfuron
Description
Flazasulfuron is a sulfonylurea herbicide used for post-emergent weed control in various crops, including rice, wheat, and sugarcane. It inhibits acetolactate synthase (ALS), an enzyme essential for amino acid biosynthesis in plants, leading to growth inhibition and eventual death. Flazasulfuron is highly effective against broadleaf weeds and some grasses, including resistant biotypes. Its synthesis involves multiple steps starting from readily available chemicals and involves reactions such as sulfonylation, amidation, and ring closure. Flazasulfuron is studied for its potential to control weeds in specific crops and to understand its effects on non-target organisms and the environment. Its mode of action and its effectiveness against resistant weeds make it a valuable herbicide, but its environmental impact needs to be carefully monitored and mitigated.'
flazasulfuron: vineyard herbicide in freshwater algae; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 93539 |
| CHEMBL ID | 1878071 |
| CHEBI ID | 81749 |
| SCHEMBL ID | 54678 |
| MeSH ID | M0453603 |
Synonyms (37)
| Synonym |
|---|
| sl-160 |
| 1-(4,6-dimethoxypyrimidin-2-yl)-3-(3-trifluoromethyl-2-pyridylsulfonyl)urea |
| ok-1166 |
| shibagen [japanese] |
| n-(((4,6-dimethoxy-2-pyrimidinyl)amino)carbonyl)-3-(trifluoromethyl)-2-pyridinesulfonamide |
| 2-pyridinesulfonamide, n-(((4,6-dimethoxy-2-pyrimidinyl)amino)carbonyl)-3-(trifluoromethyl)- |
| flazasulfuron [iso] |
| flazasulfuron |
| NCGC00164266-01 |
| 1-(4,6-dimethoxypyrimidin-2-yl)-3-[3-(trifluoromethyl)pyridin-2-yl]sulfonylurea |
| 104040-78-0 |
| 1-(4,6-dimethoxy-2-pyrimidinyl)-3-[[3-(trifluoromethyl)-2-pyridinyl]sulfonyl]urea |
| A800883 |
| C18441 |
| shibagen |
| 3sb13wwv30 , |
| hsdb 7957 |
| unii-3sb13wwv30 |
| FT-0642552 |
| n-(4,6-dimethoxy-2-pyrimidinylaminocarbonyl)-3-(trifluoromethyl)-2-pyridinesulfonamide |
| AKOS015900343 |
| flazasulfuron [mi] |
| katana |
| SCHEMBL54678 |
| CHEBI:81749 , |
| CHEMBL1878071 |
| DTXSID3034610 |
| J-001097 |
| flazasulfuron, pestanal(r), analytical standard |
| HWATZEJQIXKWQS-UHFFFAOYSA-N , |
| Q3073504 |
| flazasulfuron;1-(4,6-dimethoxypyrimidin-2-yl)-3-(3-trifluoromethyl-2-pyridylsulfonyl)urea |
| F21476 |
| flazasulfuron 100 microg/ml in acetonitrile |
| n-(4,6-dimethoxypyrimidin-2-ylcarbamoyl)-3-(trifluoromethyl)pyridine-2-sulfonamide |
| CS-0440149 |
| n-((4,6-dimethoxypyrimidin-2-yl)carbamoyl)-3-(trifluoromethyl)pyridine-2-sulfonamide |
Drug Classes (2)
| Class | Description |
|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| pyridines | Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (4)
Potency Measurements
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 30.93
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 30.93 (24.57) | | Research Supply Index | 2.30 (2.92) | | Research Growth Index | 4.83 (4.65) | | Search Engine Demand Index | 68.41 (26.88) | | Search Engine Supply Index | 3.97 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |